Clinical trials
catalyst calendar across sponsors →Studies where KZIA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
5 interventional · 2 with posted results
Held by 6 tracked-famous managers (Point72 Asset Management, L.P., MILLENNIUM MANAGEMENT LLC, JANE STREET GROUP, LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, MARSHALL WACE, LLP, +1 more) · FINRA short interest 3.4 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients With Advanced Solid TumoursNCT05114668MTD and / or a RP2D of EVT801 when administered daily to subjects with advanced or metastatic solid tumours.Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: EVT801 | Solid Tumor, Adult | 32 | 2024-11-04actual | 2025-09-02 |
| Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed GlioblastomaNCT03522298results2025-03-24Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Paxalisib (GDC-0084) | Glioblastoma, Adult | 30 | 2023-03-30actual | 2025-03-24 |
| Mass Balance Recovery, Metabolite Profile, and Metabolite Identification of [14C]-Paxalisib in Healthy Male SubjectsNCT05012670To determine the mass balance recovery after a single oral dose of carbon-14 ([14C])-PaxalisibOpen-label · Treatment | Phase 1 | Completed | Drug: [14C]-Paxalisib Capsule | Healthy | 6 | 2023-03-30actual | 2024-03-15 |
| Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer.NCT02903771results2024-09-19Determination of the Maximum Tolerated Dose (MTD)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Part A: Dose Escalation of Cantrixil, Part B: Expansion Cohort of Cantrixil | Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms | 32 | 2020-03-24actual | 2024-09-19 |
| Phenoxodiol in Treating Patients With Refractory Solid TumorsNCT00022295Treatment | Phase 1 | Completed | Drug: idronoxil | Unspecified Adult Solid Tumor, Protocol Specific | 36 | — | 2013-03-26 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19